A useful first estrogen consultation does not require arriving with the answer already chosen. It helps to bring a short account of what has changed, how it affects daily life and what you hope treatment could improve. That is different from selecting a hormone because an online menu makes it look convenient.
This guide offers questions for a clinician, not a self-screening test that grants or denies treatment. The medical and provider sources were checked September 27, 2026. No checklist can replace a personal assessment, and a commercial first position on this site does not settle which care plan is appropriate.
A complete estrogen plan should explain why this medicine fits the concern, how it will be used and how it will be reviewed.
What are we trying to treat?
Describe the symptoms in ordinary language: what happens, how often, when it started and what is most disruptive. Ask whether menopause is the likely explanation or whether another evaluation is needed. A broad symptom list on a sales page should not turn every new concern into a hormone deficiency.
Ask what a meaningful improvement would look like and when it would be reviewed. The FDA patient explanation describes approved hormone-therapy uses and emphasizes individual decision-making. A proposed treatment should have a clear purpose. It should not be sold as a guarantee of youthful appearance, prevention of dementia or an answer to every aspect of aging.
Is the proposed medicine local or systemic?
Ask for the full medicine name, intended route and treatment goal. Local low-dose vaginal therapy and systemic estrogen are not interchangeable answers to the same question. Even the word vaginal is incomplete because some products used that way provide systemic treatment.
Our local-versus-systemic guide explains the categories. If a patch or pill is proposed, the route comparison covers practical questions as well as medical context. The aim is not to choose a form without help, but to understand why the clinician thinks the specific prescription fits the problem being addressed.
Which parts of my history change the decision?
Bring a current medicine and supplement list and describe relevant personal and family history, previous operations and any unusual bleeding. The ACOG resource identifies important conditions that affect systemic hormone-therapy discussions. A website intake should lead to assessment, not be treated as independent proof that treatment is suitable.
If you do not remember which organs were removed during surgery, ask how to obtain the records. Explain existing cancer care, clotting history or other specialist treatment rather than assuming it is already visible to a new online service. The provider can then decide what further information or coordination is needed.
Do I need a uterine-protection plan?
If systemic estrogen is being considered and the uterus is present, ask what appropriate progestogen protection would be used. Understand the role of each medicine, whether they are supplied together or separately, and how the instructions will be communicated.
The estrogen-and-progesterone guide explains this without providing a schedule. If the proposal is standard low-dose local vaginal therapy, ask the clinician to explain why its protection considerations differ. Do not add, omit or stop another prescribed hormone because a general description sounds similar to your situation.
Which current label should I read?
FDA announced an initial set of approved hormone-therapy label changes in February 2026. Some prominent warnings were revised, but this did not make all products identical or remove every important risk consideration. Read the information supplied for the actual prescribed medicine.
The FDA’s current explanation says cardiovascular and breast-cancer risk information was not requested to be removed from Warnings and Precautions, and the systemic estrogen-alone endometrial-cancer boxed warning was retained. Ask the clinician or pharmacist to explain how the current information applies to the plan, rather than relying on either an old screenshot or a reassuring headline.
Is this an approved medicine or a compounded preparation?
Ask the question directly and request the product and pharmacy names. A familiar hormone ingredient, the word natural and a personalized consultation do not establish FDA approval. If compounding is proposed, ask what need the customized preparation addresses.
FDA explains the distinction between compounded drugs and approved products. The appropriate answer should be specific to the medicine being prescribed, not a claim that all of a provider’s offerings share one status. This site has not verified the exact medication that any individual applicant would receive from the services reviewed.
What will the full care plan cost?
Request separate figures for the assessment, each medicine, testing when indicated, follow-up and delivery. Clarify the supply period, insurance assumptions and any recurring authorization. Ask what happens financially if no prescription is issued or the plan changes.
The provider comparison shows why this matters: a membership headline, self-pay visit and medication starting price are different figures. The Alloy review also preserves a patch-price disagreement across two current pages. An unresolved amount should remain a question until an actual quotation answers it, not become zero in a budget.
How will we review benefit, side effects and changing needs?
Before leaving the discussion, know who to contact, how follow-up is arranged and what needs prompt assessment. Ask specifically about bleeding after menopause and bothersome effects. An online message channel is not an emergency service, and a general adjustment timeline is not permission to ignore a concerning change.
Agree on a review of the treatment goal and any practical difficulties. Keep the prescription instructions, pharmacy information and care-team contact details together. A good next step may be treatment, further evaluation or a different approach. The useful outcome is an understandable plan with a way to revisit it, rather than a prescription obtained at any cost.
Choose the questions to take with you. Your selections stay in this page and are not submitted.
0 of 6 selectedSources & reading
Sources checked September 27, 2026. Provider pages describe their own services; they do not establish clinical superiority.
- FDA: Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms ↗Federal patient and labeling explanation
- ACOG: Hormone Therapy for Menopause ↗Professional patient guidance
- FDA: February 12, 2026 approval of initial hormone-therapy label changes ↗Federal regulatory announcement
- FDA: Understanding the Risks of Compounded Drugs ↗Federal regulatory explanation
- Alloy: hormone replacement therapy ↗Provider treatment page
- Alloy: solutions and product prices ↗Provider product catalog
- NHS: Postmenopausal bleeding ↗UK public health guidance